Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Kees

Showing results (241-250 of 333) with videos related to

Pageof 34
Sort By:
The New England Journal of Medicine|August 20, 2020
Evinacumab for Homozygous Familial HypercholesterolemiaFrederick J Raal, Robert S Rosenson, Laurens F Reeskamp, et al.
Lancet (London, England)|October 6, 2014
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Evan A Stein, Robert Dufour, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 4, 2024
Unexpected gaps in knowledge of familial hypercholesterolaemia among Dutch general practitionersShirin Ibrahim, Jim N de Goeij, Nick S Nurmohamed, et al.
The New England Journal of Medicine|September 1, 2020
Evolocumab in Pediatric Heterozygous Familial HypercholesterolemiaRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
The Lancet. Diabetes & Endocrinology|September 8, 2022
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCTRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
The New England Journal of Medicine|January 14, 2011
Genetic variant of the scavenger receptor BI in humansMenno Vergeer, Suzanne J A Korporaal, Remco Franssen, et al.
Journal of the American Heart Association|August 5, 2017
Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health StudyJulian C van Capelleveen, Andrea E Bochem, S Matthijs Boekholdt, et al.
The New England Journal of Medicine|November 12, 2023
Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesA Michael Lincoff, Kirstine Brown-Frandsen, Helen M Colhoun, et al.
European Heart Journal|May 18, 2026
Homozygous familial hypercholesterolaemia: insights from the Global HICC RegistryWillemijn A M Schonck, Janneke W C M Mulder, Marina Cuchel, et al.
Journal of Lipid Research|June 4, 2014
Identification of four novel genes contributing to familial elevated plasma HDL cholesterol in humansRoshni R Singaraja, Ian Tietjen, G Kees Hovingh, et al.
Pageof 34

Showing results (241-250 of 333) with videos related to

Sort By:
Pageof 34
The New England Journal of Medicine|August 20, 2020
Evinacumab for Homozygous Familial HypercholesterolemiaFrederick J Raal, Robert S Rosenson, Laurens F Reeskamp, et al.
Lancet (London, England)|October 6, 2014
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Evan A Stein, Robert Dufour, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 4, 2024
Unexpected gaps in knowledge of familial hypercholesterolaemia among Dutch general practitionersShirin Ibrahim, Jim N de Goeij, Nick S Nurmohamed, et al.
The New England Journal of Medicine|September 1, 2020
Evolocumab in Pediatric Heterozygous Familial HypercholesterolemiaRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
The Lancet. Diabetes & Endocrinology|September 8, 2022
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCTRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
The New England Journal of Medicine|January 14, 2011
Genetic variant of the scavenger receptor BI in humansMenno Vergeer, Suzanne J A Korporaal, Remco Franssen, et al.
Journal of the American Heart Association|August 5, 2017
Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health StudyJulian C van Capelleveen, Andrea E Bochem, S Matthijs Boekholdt, et al.
The New England Journal of Medicine|November 12, 2023
Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesA Michael Lincoff, Kirstine Brown-Frandsen, Helen M Colhoun, et al.
European Heart Journal|May 18, 2026
Homozygous familial hypercholesterolaemia: insights from the Global HICC RegistryWillemijn A M Schonck, Janneke W C M Mulder, Marina Cuchel, et al.
Journal of Lipid Research|June 4, 2014
Identification of four novel genes contributing to familial elevated plasma HDL cholesterol in humansRoshni R Singaraja, Ian Tietjen, G Kees Hovingh, et al.
Pageof 34